Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer: European Journal of Cancer

O. Caffo, D. Gasparro, G. Di Lorenzo, A.D. Volta, P. Guglielmini, P. Zucali, R. Bortolus, A. Cavo, G. Ceresoli, R. Chiari, G. Fornarini, L. Fratino, A. Iaculli, M. Maruzzo, C. Masini, F. Morelli, C. Mucciarini, G. Procopio, R. Sabbatini, E. VerriS. Kinspergher, F. Maines, C. Messina, A. Veccia, M. Donini

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Patients with cancer are at increased risk of complicated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but it is still unclear if the risk of mortality is influenced by cancer type or ongoing anti-cancer treatments. An interesting debate concerning the potential relationship between androgen deprivation therapy (ADT) and SARS-CoV-2 infection has recently been opened in the case of prostate cancer (PC), and the aim of this multi-centre cohort study was to investigate the incidence and outcomes of SARS-CoV-2 infection in patients with metastatic castration-resistant prostrate cancer (mCRPC). Patients and methods: We retrospectively reviewed the clinical records of patients with mCRPC who developed SARS-CoV-2 infection, and recorded their baseline clinical characteristics, their history of PC and SARS-CoV-2 infection, and their oncological status and treatment at the time of infection. The primary study end point was the death rate and the possible impact of the patients' PC-related history and treatments on mortality. Results: Thirty-four of the 1433 patients with mCRPC attending the participating centres (2.3%) developed SARS-CoV-2 infection, 22 (64.7%) of whom were hospitalised. Most of the patients were symptomatic, the most frequent symptoms being fever (70.6%), dyspnoea (61.8%), cough (52.9%) and fatigue (38.2%). After a median follow-up of 21 days (interquartile range: 13–41), 13 patients had died (38.2%), 17 recovered (50.0%) and four (11.7%) were still infected. The number of treatments previously administered for mCRPC had a significant impact on mortality (p = 0.004). Conclusions: Our findings contribute additional data to the current debate concerning the postulated protective role of ADT, which seems to be less in patients with metastatic PC. © 2020 Elsevier Ltd
Original languageEnglish
Pages (from-to)140-146
Number of pages7
JournalEur. J. Cancer
Volume140
DOIs
Publication statusPublished - 2020

Keywords

  • Androgen deprivation therapy
  • COVID-19
  • Metastatic castration-resistant prostate cancer
  • SARS-CoV-2 infection
  • abiraterone
  • cabazitaxel
  • docetaxel
  • enzalutamide
  • steroid
  • aged
  • Article
  • castration resistant prostate cancer
  • coronavirus disease 2019
  • coughing
  • dyspnea
  • fatigue
  • fever
  • human
  • incidence
  • major clinical study
  • male
  • medical history
  • medical record review
  • metastasis
  • mortality
  • priority journal
  • retrospective study
  • Betacoronavirus
  • bone tumor
  • complication
  • Coronavirus infection
  • follow up
  • isolation and purification
  • Italy
  • multimodality cancer therapy
  • pandemic
  • pathology
  • prognosis
  • survival rate
  • very elderly
  • virology
  • virus pneumonia
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms
  • Combined Modality Therapy
  • Coronavirus Infections
  • Follow-Up Studies
  • Humans
  • Incidence
  • Male
  • Pandemics
  • Pneumonia, Viral
  • Prognosis
  • Prostatic Neoplasms, Castration-Resistant
  • Retrospective Studies
  • Survival Rate

Fingerprint Dive into the research topics of 'Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer: European Journal of Cancer'. Together they form a unique fingerprint.

Cite this